MET and non-small cell lung carcinoma: We also analyzed the activation of STAT3 in NSCLC lines bearing genomic amplification of the tyrosine kinases PDGFRA (NCI-H1703) and MET (NCI-H1993), both of which are found to be amplified or mutated in NSCLC [26], [27].